Stay updated with breaking news from Cellular Therapy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The life-changing drug, developed by Boston-based Vertex and its Swiss partner CRISPR Therapeutics, targets sickle cell disease, an inherited blood disorder that causes crippling pain.
A discusses the FDA’s investigation into the possible association between CAR-T cell therapy and secondary T-cell malignancies.
The following message was sent to members of the Department of Medicine from Dr. Kathleen Cooney, MD, MACP, chair of the Department of Medicine, and Nelson Chao, MD, MBA, chief of the Division of Hematologic Malignancies & Cellular Therapy.
(FOX40.COM) — A UC Davis Health research team has been awarded $15 million to continue their groundbreaking work on a spina bifida treatment for phase 2 of clinical trial tests. A $8.9 million grand from The California Institute for Regenerative Medicine and a match of $5.9 million from Shriner’s Children will continue the work led […]
PHILADELPHIA — The University of Pennsylvania plans to continue offering CAR-T therapy, a cancer treatment pioneered at Penn, after the Food and Drug Administration announced Tuesday an investigation into whether